LRP6 and breast carcinoma: Indeed, kallistatin could bind to the Wnt co-receptor low-density lipoprotein receptor-related protein 6 (LRP6), thus blocking Wnt/b-catenin signaling as well as Wnt-mediated growth and migration in MDA-MB-231 breast cancer cells [20].